The spliced APH-2 mRNA is detected in HTLV-2–infected cell lines and in PBMCs from HTLV-2–infected patients. (A) Total RNA was extracted from C19 and MO (HTLV-2–infected), Jurkat, and CEM (HTLV noninfected) and C91/PL (HTLV-1–infected) cell lines. RT was performed using the 24-2 primer and was followed by a seminested PCR using the 19-1/21-2 and 22-1/21-2 primers. Lanes 1 and 2 represent C19; lane 3, MO; lane 4, Jurkat; lane 5, CEM; lane 6, C91/PL; lane 7, H₂O. (B) Same experimental conditions as in panel A. Lanes 1 and 2 represent RNA extract from Jurkat cells; lanes 3 and 4, from C19 cells; lanes 5 and 6, from 590101; lanes 7 and 8, from GU; lanes 9 and 10, from Pyl116; lane 11, H₂O. (C) Same experimental conditions as in panel A. Lanes 2 and 3 represent 400 ng and 40 ng, respectively, of RNA extracted from MO cells used for RT-PCR analysis; lanes 4 and 12, H₂O; lanes 10 and 11, RNA extract from C19 cells; lane 22, RNA extract from Jurkat cells; lanes 5 to 9 and 13 to 21, RNAs extracted from PBMC of 15 HTLV-2–infected persons. (Bottom of both panels) The same samples were analyzed for the presence of GAPDH mRNA by RT-PCR. In panel A (lane 1), panel B (lanes 2, 4, 6, 8, and 10), and panel C (lanes 1 and 10), RT was omitted during the RT step. M indicates 100-bp marker. The 2 parts of the image shown in panel C (top panel) are from the same gel.